Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News Tags: PepGen

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FibroGen Italfarmaco NS Pharma PepGen Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Solid Biosciences Wave Life Sciences
October 17, 2023

PepGen Shares Q3 Newsletter

PepGen shares Q3 updates via newsletter summary.
Read More
July 21, 2023

PepGen Shares 2023 Q2 Newsletter

PepGen shares their 2023 Q2 newsletter
Read More
May 19, 2023

PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne

PepGen announces clearance by Health Canada of CTA for PGN-EDO51 to begin the Phase 2 Clinical Trial, CONNECT1-EDO51
Read More
April 10, 2023

PepGen Shares Quarterly Newsletter

PepGen announces quarterly newsletter on April 7, 2023.
Read More
September 28, 2022

PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen announces the completed results from its Phase 1 healthy normal volunteer (HNV) trial of PGN-EDO51 for Duchenne.
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2023 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Accessible Vehicle Fund Applications Open

    Apply Today